EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1099-1104 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1099 - 1104
Section II - La réalité clinique
DOI https://doi.org/10.1051/medsci/200925121099
Published online 15 December 2009
  1. Folkman J.Tumor angiogenesis : therapeutic implications. N Engl J Med 1971; 285 : 1182–6. [Google Scholar]
  2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2 : 795–803. [Google Scholar]
  3. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia : role of the HIF system. Nat Med 2003; 9 : 677–84. [Google Scholar]
  4. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73 : 931–4. [Google Scholar]
  5. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56 : 172–81. [Google Scholar]
  6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 : 2335–42. [Google Scholar]
  7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006; 355 : 2542–50. [Google Scholar]
  8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357 : 2666–76. [Google Scholar]
  9. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma : CALGB 90206. J Clin Oncol 2008; 26 : 5422–8. [Google Scholar]
  10. Halimi JM, Azizi M, Bobrie G, et al. Vascular and renal effects of antiangiogenic therapy. Nephrol Ther 2008; 4 : 602–15. [Google Scholar]
  11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25 : 4722–9. [Google Scholar]
  12. Hunt S. Technology evaluation : IMC-1C11, ImClone systems. Curr Opin Mol Ther 2001; 3 : 418–24. [Google Scholar]
  13. Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006; 345 : 438–45. [Google Scholar]
  14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 : 1419–31. [Google Scholar]
  15. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin®) treatment of proliferative diabetic retinopathy complicated by vitrous hemorrhage. Retina 2006; 26 : 275–8. [Google Scholar]
  16. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005; 14 : 1–17. [Google Scholar]
  17. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97 : 512–23. [Google Scholar]
  18. Shen J, Vil MD, Zhang H, et al. An antibody directed against PDGF receptor beta enhances the anti-tumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 2007; 357 : 1142–7. [Google Scholar]
  19. Javerzat S, Auguste P, Bikfalvi A. The role of Fibroblast Growth Factor in vascular development. Trends Mol Med 2002; 8 : 483–9 [Google Scholar]
  20. Shimada N, Ishii T, Imada T, et al. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependant mouse mammary tumors in vivo. Clin Cancer Res 2005; 11 : 3897–904. [Google Scholar]
  21. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37 : 19–29. [Google Scholar]
  22. Tuxhorn JA, Mac Alhany SJ, Yag F, et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62 : 6021–5. [Google Scholar]
  23. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277 : 55–60. [Google Scholar]
  24. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of Angiopoietin-2.Cancer Cell 2004; 6 : 507–16 [Google Scholar]
  25. Delbaldo C, Raymond E, Vera K, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin®), a humanized monoclonal antibody against alphaVbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008; 26 : 35–43. [Google Scholar]
  26. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of Interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20 : 264–9. [Google Scholar]
  27. Galaup A, Germain S. Blocking PlGF, a future in anti-angiogenic therapy ? Med Sci (Paris) 2008; 24 : 459–62. [Google Scholar]
  28. Escudier B, Gross-Goupil M. Revolution in treatment of renal carcinoma : molecular rational and clinical approach. Med Sci (Paris) 2008; 24 : 697–9 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.